SB-001 (Anti-COVID-19 mAb)
AcadeMab has discovered a panel of fully human monoclonal antibodies (mAbs) directly against receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein from SARS-CoV-2 vaccine recipients by human single B cell technology. One of the mAbs showed a comparable neutralization ability (IC50 = 11.4 and 4.3 ng/ml for Omicron variants BA.1 and BA.2, respectively) with the marketed mAbs. For Omicron BA.2, Bebtelovimab shows an IC50 value of 4.0 ng/ml and Evusheld reported IC50 ranging from 9.8 to 43 ng/ml. Furthermore, another hAb had broad-spectrum activity against multiple variants of concern (VOCs), including Delta variant and all tested Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 subvariants.
Notably, this panel of antibodies have strong binding activity to RBD and can cover the strains of wild type, Alpha, Beta, Kappa, Delta, Gamma, Omicron BA.1, BA.2, and BA.4/5 variants. These neutralizing human antibodies targeting the RBD domain of SARS-CoV-2 spike protein have potential in prophylactic or therapeutic applications for COVID-19.
Indication and stage